Satellos Bioscience (DE:0IT)
FRANKFURT:0IT
0IT Stock Chart & Stats
€7.30
€0.03(5.26%)
At close: 4:00 PM EST
€7.30
€0.03(5.26%)
Day’s Range― - ―
52-Week Range€3.89 - €11.38
Previous CloseN/A
VolumeN/A
Average Volume (3M)257.00
Market Cap
€124.22M
Enterprise Value€41.10M
Total Cash (Recent Filing)€69.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 31, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding20,831,190
10 Day Avg. Volume471
30 Day Avg. Volume257
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.88Price Target Upside158.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.79
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free balance sheet materially lowers insolvency and interest-rate risk for a pre-commercial biotech, giving management greater flexibility to fund R&D and clinical programs. This enhances optionality on financing choices and reduces fixed financial obligations over the medium term.
Focused Therapeutic Niche (DMD)Concentration on skeletal muscle disorders, including Duchenne muscular dystrophy, positions the company in a high unmet-need area with durable structural demand, clearer regulatory pathways for orphan drugs, and potential for premium pricing if clinical programs succeed, improving long-term commercial prospects.
Lean Operating StructureA very small headcount implies a lean cost base, which can extend cash runway and allow focused allocation of scarce resources to core R&D activities. For a pre-revenue developer, lower fixed overhead enhances operational flexibility while seeking financing or partnerships.
Bears Say
Pre-revenue With Widening LossesPersistent pre-revenue status combined with a materially wider TTM net loss (~$28.5M) means ongoing R&D spending without commercial offset. This elevates financing requirements, increases dilution risk for shareholders, and ties long-term viability to successful clinical milestones.
Consistent Negative Free Cash FlowSustained negative operating cash flow and roughly -$25.8M TTM free cash flow indicate the business is consuming capital, not generating it. Continued cash burn forces dependence on external funding or partnerships, raising execution and dilution risk during multi-year development cycles.
Very Weak Profitability / Negative ROEDeeply negative ROE (~-51% TTM) and volatile equity reflect accumulated losses and capital activity, signaling poor capital efficiency. Over the medium term this undermines investor returns and increases the likelihood of dilutive financings if clinical progress does not quickly translate to value creation.
Satellos Bioscience News
0IT FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was €3.89 and its highest was €11.38 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is €124.22M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 66 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on May 15, 2026. The company reported -€0.452 earnings per share for the quarter, missing the consensus estimate of -€0.418 by -€0.033.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.44.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 20,831,190 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -€0.452 in its last earnings report, missing expectations of -€0.418. Following the earnings report the stock price went up 0.826%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in DE:0IT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Satellos Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.88 (158.59% Upside)
€18.88 (158.59% Upside)
Blogger Sentiment
Bullish
DE:0IT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €128.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-51.42%
Trailing 12-Months
Asset Growth
69.55%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
0IT Stock 12 Month Forecast
Average Price Target
€18.88
▲(158.59% Upside)
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
Helix BioPharma
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---